AstraZeneca, FibroGen's roxadustat hit with tough safety questions in FDA review ahead of key ...

Retrieved on: 2021-07-13 15:48:46

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca, FibroGen's roxadustat hit with tough safety questions in FDA review ahead of key .... View article details on hiswai:

Excerpt

The FDA frowns upon the blood clotting risk of FibroGen and AstraZeneca's potentially first-in-class anemia drug roxadustat ahead of a closely ...

Article found on: www.fiercepharma.com